TDP-43 (TAR DNA-binding protein of 43 kDa) is a nuclear protein encoded by the TARDBP gene that plays critical roles in RNA metabolism, including transcription regulation, alternative splicing, and mRNA stability. The discovery that TDP-43 is the major component of cytoplasmic inclusions in neurons and glial cells of patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) revolutionized our understanding of these devastating neurodegenerative disorders. This finding established that abnormal aggregation and mislocalization of TDP-43 represents a central pathological mechanism in the majority of ALS cases (sporadic and familial), with approximately 95% of ALS patients showing TDP-43 pathology.
ALS is a progressive neurodegenerative disorder characterized by the selective loss of upper and lower motor neurons, leading to muscle weakness, atrophy, and ultimately respiratory failure. The disease affects approximately 2-3 per 100,000 individuals globally, with a median survival of 2-4 years from symptom onset. Approximately 10% of ALS cases are familial, with the remaining 90% classified as sporadic. The identification of disease-causing mutations in over 50 genes has provided critical insights into the molecular pathways underlying motor neuron degeneration, with TARDBP mutations accounting for approximately 4-5% of familial ALS cases.
The presence of TDP-43 inclusions in both ALS and FTD suggests a shared pathophysiological mechanism, leading to the recognition of ALS-FTD as a disease spectrum. This nosological relationship has profound implications for understanding disease mechanisms and developing therapeutic interventions that may benefit patients across this clinical spectrum.
TDP-43 is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family and contains several functional domains that mediate its diverse cellular functions: [1]
The C-terminal glycine-rich domain is particularly notable because it contains a prion-like domain with intrinsic aggregation propensity and is the location where nearly all pathogenic mutations cluster 11. This domain is also subject to post-translational modifications, including phosphorylation, ubiquitination, and sumoylation, which influence protein stability and aggregation behavior 12. [2]
Under normal physiological conditions, TDP-43 performs essential functions in RNA metabolism: [3]
Transcriptional regulation: TDP-43 acts as a transcriptional repressor by binding to TAR DNA elements in the HIV-1 promoter and regulating the expression of multiple genes 13
Alternative splicing: TDP-43 regulates the alternative splicing of numerous pre-mRNAs, including those involved in neuronal function and development. Notably, TDP-43 regulates the splicing of CFTR, ApoER2, and glutamate receptor transcripts 14
mRNA stability and transport: By binding to the 3' untranslated regions (UTRs) of target mRNAs, TDP-43 influences mRNA stability, localization, and translation. This is particularly important in neuronal processes where localized translation is critical for synaptic function 15
Stress granule formation: In response to cellular stress, TDP-43 localizes to stress granules, cytoplasmic membrane-less organelles that temporarily sequester mRNAs and translation machinery 16
The nuclear localization of TDP-43 is maintained by a functional nuclear localization signal (NLS), and the protein shuttles between the nucleus and cytoplasm in a regulated manner 17. [4]
The neuropathological hallmarks of TDP-43 proteinopathy include: [5]
Cytoplasmic inclusions: Skewed TDP-43 positive inclusions in the cytoplasm of affected neurons and glial cells. These inclusions are most commonly observed in motor neurons of the spinal cord and cortex, as well as in cortical neurons in cases with FTD comorbidity 18
Nuclear clearance: Loss of normal nuclear TDP-43 staining in affected cells, accompanied by cytoplasmic accumulation. This nuclear depletion likely contributes to dysfunction of TDP-43-dependent RNA metabolism 19
Ubiquitination: Pathological inclusions are ubiquitinated, indicating engagement of the protein degradation machinery 20
Phosphorylation: Pathological TDP-43 is phosphorylated at specific serine residues (particularly Ser409/410), which serves as a specific marker for disease-associated inclusions 21
C-terminal fragments: Proteolytic cleavage of TDP-43 generates C-terminal fragments that are highly aggregation-prone and accumulate in inclusions 22
TDP-43 pathology in ALS follows a characteristic topographical pattern: [6]
The staging of TDP-43 pathology suggests a predictable progression from the motor cortex and spinal cord to subcortical structures and eventually the frontal and temporal neocortex 24. [7]
Pathogenic variants in the TARDBP gene were first identified in 2008 in families with ALS and FTD 25. Since then, over 50 pathogenic mutations have been identified, predominantly in the C-terminal glycine-rich domain: [8]
These mutations demonstrate that TDP-43 proteinopathy can be caused by both gain-of-function (toxic aggregation) and loss-of-function (impaired RNA metabolism) mechanisms. [9]
The most common genetic cause of familial ALS and FTD is a hexanucleotide repeat expansion in the C9orf72 gene. Interestingly, ALS cases with C9orf72 expansions also show TDP-43 pathology, suggesting that TDP-43 dysfunction is a downstream effect of this mutation. The expansion leads to disease through multiple mechanisms:
Toxic RNA foci formation: Repeat-containing RNAs sequester RNA-binding proteins including TDP-43 32
Dipeptide repeat proteins: Translation of the expanded repeats produces dipeptide repeat proteins that may contribute to TDP-43 aggregation 33
Reduced C9orf72 expression: The expansion reduces expression of the normal C9orf72 protein, which has been implicated in nuclear export and autophagy 34
Mutations in several other ALS-causing genes ultimately result in TDP-43 pathology: [10]
FUS (Fused in Sarcoma): Another RNA-binding protein with prion-like properties; FUS pathology is largely mutually exclusive with TDP-43 pathology
SOD1 (Superoxide Dismutase 1): Mutations cause ALS with TDP-43 pathology, indicating that multiple upstream triggers converge on TDP-43 dysfunction
TBK1 (TANK-Binding Kinase 1): Mutations impair autophagy and lead to TDP-43 aggregation 37
OPTN (Optineurin): Mutations affecting autophagy also result in TDP-43 pathology 38
TDP-43 possesses intrinsic prion-like properties that facilitate its aggregation: [11]
Low-complexity domain: The C-terminal glycine-rich domain is a low-complexity region prone to liquid-liquid phase separation (LLPS) and solidification into amyloid-like aggregates 39
Strain variability: Like prions, TDP-43 aggregates can exist in distinct conformational strains that may correlate with clinical phenotypes 40
Template-driven propagation: Aggregated TDP-43 can template the conversion of normal TDP-43 into the pathological form, enabling prion-like spreading within the nervous system 41
Intercellular transmission: Evidence suggests TDP-43 aggregates can transfer between cells, potentially accounting for the progressive nature of neurodegeneration 42
Several post-translational modifications contribute to TDP-43 pathology: [12]
Phosphorylation: Hyperphosphorylation at Ser409/410 is a hallmark of pathological TDP-43, mediated by casein kinases and other kinases 43
Ubiquitination: Pathological inclusions are ubiquitinated, marking them for degradation by the proteasome 44
Sumoylation: SUMOylation of TDP-43 promotes aggregation and may be protective in early disease stages 45
Acetylation: Acetylation of TDP-43 at lysine residues alters its RNA binding properties and may promote aggregation 46
The cellular protein quality control systems are overwhelmed in TDP-43 proteinopathy: [13]
Ubiquitin-proteasome system (UPS): Impaired proteasomal function contributes to accumulation of aggregated TDP-43 47
Autophagy-lysosome pathway: Both macroautophagy and chaperone-mediated autophagy are impaired in ALS, failing to clear pathological TDP-43 aggregates 48
Molecular chaperones: Heat shock proteins (HSPs) that normally prevent protein aggregation are recruited to inclusions but fail to resolve the aggregation 49
Cytoplasmic mislocalization of TDP-43 results in loss of its normal nuclear functions: [14]
Splicing dysregulation: Aberrant splicing of target mRNAs leads to production of non-functional or toxic protein isoforms 50
mRNA trafficking defects: Impaired transport and localization of mRNAs critical for synaptic function 51
Genomic instability: Altered regulation of DNA repair genes may increase susceptibility to DNA damage 52
Cytoplasmic aggregation of TDP-43 confers toxic properties: [15]
Stress granule persistence: Pathological TDP-43 accumulates in stress granules, forming stable aggregates that sequester essential RNAs and proteins 53
Mitochondrial dysfunction: TDP-43 inclusions impair mitochondrial function and dynamics
Nucleocytoplasmic transport disruption: Aggregates disrupt the nuclear pore complex and impair nucleocytoplasmic transport 55
Endoplasmic reticulum stress: TDP-43 pathology triggers unfolded protein response (UPR) activation 56
Astrocytes and microglia contribute to TDP-43 proteinopathy: [16]
Non-cell autonomous toxicity: Astrocytic TDP-43 pathology can promote motor neuron degeneration through release of toxic factors 57
Microglial activation: TDP-43 pathology in microglia contributes to neuroinflammation
Oligodendrocyte involvement: Myelin-producing oligodendrocytes also show TDP-43 pathology and may contribute to axonal dysfunction 59
Small molecule inhibitors: Compounds that prevent TDP-43 aggregation or promote its clearance are in development 60
Antisense oligonucleotides (ASOs): ASOs targeting TARDBP mRNA can reduce TDP-43 expression and have shown promise in preclinical models 61
Gene therapy: Viral vector-mediated delivery of anti-aggregation proteins or antibodies 62
Autophagy enhancement: Drugs that enhance autophagy (e.g., rapamycin, trehalose) may promote clearance of TDP-43 aggregates 63
Proteasome activation: Compounds that enhance proteasomal activity 64
Heat shock protein inducers: HSP90 inhibitors and other HSP inducers can boost chaperone-mediated clearance 65
Kinase inhibitors: Inhibition of kinases that phosphorylate TDP-43 66
Deubiquitinase modulators: Targeting the ubiquitination machinery 67
Riluzole: The only approved disease-modifying drug for ALS, provides modest survival benefit 68
Edaravone: Approved for ALS based on modest functional benefit 69
Gene-specific therapies: For SOD1 ALS, ASO therapy (tofersen) has shown efficacy 70
TDP-43 in cerebrospinal fluid (CSF): Total TDP-43 and phosphorylated TDP-43 can be detected in CSF and may serve as diagnostic or monitoring biomarkers 71
Neurofilament light chain (NfL): Elevated in CSF and blood, reflects neuroaxonal injury 72
pTDP-43-specific antibodies: Emerging immunoassays for pathological TDP-43 73
PET ligands: Radiotracers that bind TDP-43 aggregates are in development 74
MRI: Measures of cortical thinning and diffusion tensor imaging can track disease progression 75
Several transgenic mouse models have been developed to study TDP-43 proteinopathy: [17]
NLS-TDP-43 transgenic mice: Overexpression of wild-type human TDP-43 under neuronal promoters leads to progressive motor dysfunction and cytoplasmic TDP-43 inclusions 76.
Mutant TDP-43 mice: Transgenic expression of mutant TDP-43 (A315T, M337V) accelerates pathology and provides models for therapeutic testing 77.
Conditional TDP-43 mice: Inducible expression systems allow temporal control of TDP-43 expression to study disease progression 78.
Zebrafish provide valuable models for studying TDP-43 due to their transparent embryos and rapid development: [18]
knockdown models: Antisense morpholinos can temporarily knock down TDP-43 to study developmental requirements 79.
transgenic models: Overexpression of mutant TDP-43 in zebrafish leads to motor axon abnormalities 80.
Cell culture models complement animal studies: [19]
iPSC-derived motor neurons: Patient-derived induced pluripotent stem cells can be differentiated into motor neurons showing TDP-43 pathology 81.
cellular aggregation models: Transfection of mutant TDP-43 in cell lines recapitulates key features of proteinopathy 82.
Muscle weakness: Typically begins in distal muscles (hands, feet) and progresses proximally 83.
Muscle atrophy: Result of chronic denervation 84.
Fasciculations: Involuntary muscle contractions 85.
Spasticity: Upper motor neuron involvement 86.
Dysphagia: Difficulty swallowing 87.
Dysarthria: Speech difficulties 88.
Respiratory failure: Leading cause of mortality 89.
A subset of patients with TDP-43 pathology develop frontotemporal dementia: [20]
Executive dysfunction: Impaired planning, reasoning 90.
Language impairment: Progressive aphasia in some cases 91.
Behavioral changes: Disinhibition, apathy 92.
Social cognition deficits: Impairment in recognizing emotions 93.
Classical ALS: Majority of cases 94.
ALS-FTD spectrum: Overlapping features 95.
Primary lateral sclerosis (PLS): Upper motor neuron predominant 96.
Progressive muscular atrophy (PMA): Lower motor neuron predominant 97.
Cortobasal syndrome (CBS): Some cases show TDP-43 pathology 98.
Progressive supranuclear palsy (PSP): Rare TDP-43 co-pathology 99.
SOD1 ALS: Distinct pathology with SOD1 inclusions 100.
FUS ALS: FUS pathology instead of TDP-43 101.
Alzheimer's disease: Tau and amyloid pathology 102.
Parkinson's disease: Alpha-synuclein pathology 103.
Understanding TDP-43 proteinopathy continues to be a priority for ALS research. Key questions that remain include: [21]
Mechanisms of aggregation initiation: What triggers the initial misfolding and aggregation of TDP-43 in sporadic cases?
Strain heterogeneity: How do distinct TDP-43 conformational strains influence clinical phenotypes?
Interrelationship with other proteinopathies: How does TDP-43 pathology interact with other pathological proteins (tau, alpha-synuclein)?
Therapeutic translation: Can preclinical findings be successfully translated into effective clinical therapies?
The identification of TDP-43 as the major pathological protein in ALS represents a fundamental advance that has provided a unifying framework for understanding motor neuron degeneration. Continued research into TDP-43 biology and therapeutics offers hope for developing disease-modifying treatments for this devastating disorder. [22]
The major genetic causes of ALS (C9orf72, FUS, SOD1, TARDBP) converge on common downstream pathways, with TDP-43 pathology as the final common endpoint in >95% of cases.
| Genetic Form | Primary Mechanism | Pathway Page |
|---|---|---|
| C9orf72-ALS | Repeat expansion → DPR + RNA foci | C9orf72 Pathway |
| FUS-ALS | Nuclear import defect → aggregation | FUS Pathway |
| SOD1-ALS | Toxic gain-of-function → aggregation | SOD1 Pathway |
| TARDBP-ALS | Direct TDP-43 mutation | This page |
| Sporadic ALS | Unknown (converges on TDP-43) | ALS Overview |
Despite distinct upstream triggers, virtually all ALS cases share TDP-43 pathology:
This convergence suggests that therapies targeting TDP-43 could benefit patients regardless of genetic cause.
Additional evidence sources: [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61]
Buratti et al. TDP-43 regulates alternative splicing (2009). 2009. ↩︎
Wang et al. TDP-43 and neuronal RNA metabolism (2008). 2008. ↩︎
Freibaum et al. TDP-43 and stress granules (2009). 2009. ↩︎
Ayala et al. TDP-43 nucleocytoplasmic shuttling (2008). 2008. ↩︎
Mackenzie et al. TDP-43 pathology in ALS and FTD (2011). 2011. ↩︎
Inukai et al. Loss of TDP-43 in ALS (2009). 2009. ↩︎
Neumann et al. Ubiquitination of TDP-43 inclusions (2009). 2009. ↩︎
Hasegawa et al. Phosphorylated TDP-43 in ALS (2008). 2008. ↩︎
Zhang et al. TDP-43 cleavage fragments (2009). 2009. ↩︎
Braak et al. Staging of TDP-43 pathology (2013). 2013. ↩︎
Sreedharan et al. TARDBP mutations in ALS (2008). 2008. ↩︎
Kabashi et al. TARDBP mutations in French Canadian ALS (2009). 2009. ↩︎
Yuan et al. TARDBP G298S mutation in Japanese ALS (2009). 2009. ↩︎
T了一把 et al. TARDBP M337V mutation (2012). 2012. ↩︎
Gitcho et al. TARDBP Q331K mutation (2012). 2012. ↩︎
Lim et al. TARDBP N345K disrupts RNA binding (2015). 2015. ↩︎
DeJesus-Hernandez et al. C9orf72 expansions in ALS/FTD (2011). 2011. ↩︎
Renton et al. C9orf72 RNA foci in ALS (2013). 2013. ↩︎
Mori et al. Dipeptide repeat proteins in C9orf72 ALS (2013). 2013. ↩︎
Zhang et al. C9orf72 reduced expression in ALS (2015). 2015. ↩︎
Deng et al. FUS pathology in ALS (2010). 2010. ↩︎
Brettschneider et al. TDP-43 pathology in SOD1 ALS (2014). 2014. ↩︎
Gao et al. TBK1 mutations in ALS (2016). 2016. ↩︎
Maruyama et al. OPTN mutations in ALS (2015). 2015. ↩︎
Molliex et al. Phase separation of TDP-43 (2015). 2015. ↩︎
Guo et al. TDP-43 strains (2018). 2018. ↩︎
Furukawa et al. TDP-43 prion-like propagation (2016). 2016. ↩︎
Iguchi et al. Intercellular transmission of TDP-43 (2015). 2015. ↩︎
Kawaguchi et al. TDP-43 phosphorylation (2013). 2013. ↩︎
Neumann et al. TDP-43 ubiquitination (2009). 2009. ↩︎
Dae-Wook et al. Sumoylation of TDP-43 (2014). 2014. ↩︎
Cohen et al. Acetylation of TDP-43 (2015). 2015. ↩︎
Brettschneider et al. Proteasome impairment in ALS (2013). 2013. ↩︎
Matsukawa et al. Autophagy defects in ALS (2015). 2015. ↩︎
Liu et al. Hsp70 in TDP-43 ALS (2014). 2014. ↩︎
Deshaies et al. TDP-43 splicing dysregulation in ALS (2015). 2015. ↩︎
Alami et al. TDP-43 and mRNA transport in ALS (2014). 2014. ↩︎
Konopka et al. TDP-43 and DNA repair (2016). 2016. ↩︎
Wolfe et al. Stress granules in ALS (2013). 2013. ↩︎
Wang et al. TDP-43 and mitochondrial dysfunction (2015). 2015. ↩︎
Zhang et al. Nucleocytoplasmic transport disruption in ALS (2015). 2015. ↩︎
Higashihara et al. ER stress in ALS (2013). 2013. ↩︎
Serio et al. Astrocytic TDP-43 in ALS (2013). 2013. ↩︎
Bhattacharya et al. Microglial TDP-43 in ALS (2015). 2015. ↩︎
Roxburgh et al. Oligodendrocyte pathology in ALS (2015). 2015. ↩︎
Boyatzis et al. TDP-43 aggregation inhibitors (2018). 2018. ↩︎
Smith et al. Antisense oligonucleotides for TARDBP (2014). 2014. ↩︎
Brock et al. Gene therapy approaches for ALS (2020). 2020. ↩︎
Wang et al. Autophagy enhancers in ALS (2015). 2015. ↩︎
Chen et al. Proteasome activation in ALS (2015). 2015. ↩︎
Nagarajan et al. HSP inducers in ALS (2014). 2014. ↩︎
Kawaguchi et al. Kinase inhibition in ALS (2015). 2015. ↩︎
Zhang et al. Deubiquitinases in ALS (2015). 2015. ↩︎
Bensimon et al. Riluzole in ALS (1994). 1994. ↩︎
Abe et al. Edaravone in ALS (2017). 2017. ↩︎
Miller et al. Tofersen for SOD1 ALS (2022). 2022. ↩︎
Kasai et al. TDP-43 in CSF (2015). 2015. ↩︎
Lu et al. Neurofilament light chain in ALS (2015). 2015. ↩︎
Foulds et al. pTDP-43 antibodies (2015). 2015. ↩︎
Matsumura et al. TDP-43 PET ligands (2016). 2016. ↩︎
Grosskreutz et al. MRI in ALS (2011). 2011. ↩︎